
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Indira IVF announces global collaboration for male infertility research

November 20, 2026 | News

To help strengthen the understanding of sperm genomic integrity



Indira IVF Hospital has announced an international research collaboration with Prof. Sandro C. Esteves of Androfert, Brazil, Bonraybio Co., Taiwan, and ADVY Bioscience, India to undertake prospective clinical studies aimed at advancing the scientific understanding of male infertility.

The research will examine the role of double-strand DNA breaks (DSBs) in sperm and their impact on reproductive and clinical outcomes in assisted reproductive technology (ART).

The research programme will examine the relationship between double-stranded DNA breaks in sperm and reproductive outcomes with the objective of identifying the threshold at which these breaks may begin to impact clinical outcomes including live birth rates.

Prof. Sandro C. Esteves, Medical Director of Androfert, Brazil and a globally recognised expert in male infertility and reproductive medicine, will co-lead the research initiative with Dr Vipin Chandra, who will lead this investigation and global collaboration from Indira IVF.

Male infertility accounts for nearly 40% of infertility cases worldwide. While conventional sperm DNA fragmentation testing provides important insights into sperm health, the impact of sperm DNA double-strand breaks remains insufficiently understood. Through this research, the aim is to help strengthen the understanding of sperm genomic integrity and support the development of more precise diagnostic approaches and treatment strategies in assisted reproductive technology.

Prof. Sandro C. Esteves, Medical Director, Androfert, Brazil stated, “Through this collaboration, we aim to investigate how double-strand DNA breaks influence fertilisation and embryo viability. By generating evidence on the thresholds at which these breaks may become clinically significant, we hope to strengthen understanding of male infertility and enable science-driven fertility care.”

Brown Hsu, CEO, Bonraybio Co., Taiwan, commented, “Advancements in reproductive medicine require accurate and reliable diagnostic technologies. Through this collaboration, we look forward to supporting the generation of clinical evidence that may

contribute to a better understanding of sperm genomic integrity and its impact on reproductive outcomes.”

The collaboration brings together complementary expertise in clinical research, reproductive medicine, and advanced diagnostics. Prof. Sandro C. Esteves will contribute his expertise in male infertility while Bonraybio will support through its specialised diagnostic technologies for assessing sperm genomic integrity. ADVY Biosciences will support the diagnostic research ecosystem; and Indira IVF will lead the clinical research activities and provide study materials, methodologies, analytical frameworks, and data required for research activities across the programme.